Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEG-catalase
- Development stage
- Unknown
- Lead developer
- Enzon Pharmaceuticals
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal, Intravenous
01
Overview
PEG-catalase is a PEGylated formulation of the antioxidant enzyme catalase, which catalyzes the decomposition of hydrogen peroxide ($H_2O_2$) into water and oxygen. By conjugating catalase with polyethylene glycol (PEG), the enzyme's circulating half-life is significantly prolonged and its immunogenicity is reduced. Originally developed as a therapeutic candidate by Enzon and Sterling in the late 1980s and early 1990s, PEG-catalase was investigated for various conditions involving oxidative stress and reactive oxygen species (ROS) mediated tissue injury, such as acute respiratory failure, ischemia-reperfusion injury, and inflammation. However, it did not advance to clinical trials or commercial approval and is currently used primarily as a research reagent to study redox biology, oxidative stress, and cellular signaling pathways.
- Other names
- PEG-CATPEGylated catalasepolyethylene glycol-conjugated catalasepolyethylene glycol-modified catalase
Beyond the preview
Go deeper on PEG-catalase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEG-catalase.